P1262 Longitudinal trends in benchmarking performance in Inflammatory Bowel Disease care amongst Australasian centres: A real-world registry study from the Crohn’s Colitis Cure Data Insights Program

Abstract Background Inflammatory bowel disease (IBD) is highly prevalent in Australia and New Zealand, posing an ongoing healthcare delivery challenge. We assessed longitudinal trends in care quality and clinical outcomes across ten Australasian centres, aiming to measure performance, establish benchmarks, and evaluate the impact of implementing a clinical quality registry (CQR) on key quality indicators over time. Methods Crohn’s Colitis Care (CCCare) is a cloud-based IBD-specific electronic medical record. Deidentified data prospectively entered during routine care flow to a Clinical Quality Registry (CQR). Sites with 100 people assessed annually from 2021-2024 were included. Data were evaluated using chi-squared tests for trend (categorical variables) and Kruskal-Wallis tests (continuous variables). Post-hoc pairwise comparisons were performed. Results In 2024, 5,609 people with IBD were included from 10 sites of whom, 60.7% (n = 3,407) had Crohn’s disease, 44.2% (n = 2,479) ulcerative colitis, and 2.4% (n = 137) IBD-unclassified. Gender distribution was balanced (49.3% male, 48.9% female). Median age was 42.6 years (IQR 32.1–57.0) and disease duration was 11.5 years (IQR 5.7–19.5). Most people resided in Australia (79.3%, n = 4449) and 28.3% (n = 1586) in New Zealand. Over the four-year period, the use of advanced therapies increased from 49.9% to 53.5% (p 0.001), with a reduction in time to initiation (median 5.8 to 4.7 years, p 0.001). Hospitalisation and surgery rates declined (5.1% to 2.7% and 4.0% to 1.9%, respectively; p 0.001). Mean annual time out of role fell from 20.9 days to 1.9 days (p 0.001), with no difference after 2022. Endoscopic and composite endoscopic and radiological remission rates improved (45.2% to 57.9% and 37.6% to 45.8% respectively; p 0.001). Documentation of BMI, smoking status and gender all declined (p 0.001), while waist circumference recording improved from 0.2% to 6.3% (p 0.001). Conclusion Over four years, improvements in remission outcomes, hospitalisation, and surgery rates, alongside increased and earlier use of advanced therapies, suggest a shift toward more proactive IBD care. These changes may reflect the influence of structured data capture and clinical focus prompted by a quality registry. Continued implementation of platforms to track and share care outcomes, such as CCCare is essential to optimise performance and guide improvement in IBD care. Conflict of interest: Wu, Rodger: No conflict of interest Su, Wai Kin: No conflict of interest Wilson, William: No conflict of interest Caquilpan, Victor: No conflict of interest Andrews, Jane Mary: Grant: The work I will present was funded via CCCure. CCCure’s funding sources include grants for research and payments for data reports from Pharma including AbbVie, J&J, Takeda, Celltrion, Falk, Ferring, BMS, Janssen, Pfizer, Sandoz Connor, Susan Jane: Grant: Research Support: Abbvie, Agency for Clinical Innovation, Amgen, BMS, Chiesi, Celltrion, DrFalk, Ferring, Janssen, Medical Research Future Fund, Pfizer, South Western Sydney Local Health District, Sydney Partnership for Health, Research and Enterprise, Takeda and The Leona M and Harry B Helmsley Charitable Trust Personal Fees: Ad Boards: Abbvie, Amgen, BMS, Celltrion, Eli Lilly, Ferring, GSK, Janssen, Organon, Pfizer, Takeda Speaker Fees: Abbvie, Cornerstones Health, Dr Falk, Ferring, Janssen, Pfizer, Sandoz, Sydney IBD School, Takeda Educational Support: DrFalk, Sandoz, Takeda Ghaly, Simon: Speaker fees, research grants and travel grants from Dr. Falk pharma, Janssen, Pfizer, AbbVie, Sandoz and Ferring and served on advisory boards for Pfizer and AbbVie.